(BNR) Brenntag SE - Ratings and Ratios
Chemicals, Ingredients, Lubricants, Pharma, Nutrition
BNR EPS (Earnings per Share)
BNR Revenue
Description: BNR Brenntag SE
Brenntag SE is a global leader in chemical distribution, operating in multiple regions including Europe, North America, and Asia. The company provides a range of services including just-in-time delivery, product mixing, and inventory management, as well as technical and formulation support to various industries such as nutrition, pharma, and industrial markets.
With a history dating back to 1874, Brenntag has established itself as a trusted partner for suppliers and customers alike, offering a comprehensive portfolio of chemicals and ingredients. The companys two business segments, Brenntag Essentials and Brenntag Specialties, cater to different customer needs, providing a tailored approach to the diverse industries they serve.
From a financial perspective, Brenntags market capitalization stands at approximately €8.05 billion, with a forward P/E ratio of 10.86, indicating a relatively attractive valuation. The companys return on equity (RoE) is 11.63%, suggesting a decent level of profitability. Additionally, Brenntags dividend yield can be considered a relevant KPI, as it reflects the companys ability to distribute profits to shareholders. As a trading analyst, it would be essential to monitor Brenntags cash flow generation, debt-to-equity ratio, and operating margins to gauge the companys financial health and potential for future growth.
To further evaluate Brenntags performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of sales can provide valuable insights. For instance, a steady increase in revenue, accompanied by stable or expanding gross margins, could indicate a strong market position and effective cost management. Moreover, analyzing Brenntags industry-specific trends, such as the demand for specialty chemicals in the coatings and adhesives sector, can help identify potential opportunities and challenges.
BNR Stock Overview
| Market Cap in USD | 9,321m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
BNR Stock Ratings
| Growth Rating | -14.0% |
| Fundamental | 53.1% |
| Dividend Rating | 71.4% |
| Return 12m vs S&P 500 | -26.1% |
| Analyst Rating | - |
BNR Dividends
| Dividend Yield 12m | 3.73% |
| Yield on Cost 5y | 4.63% |
| Annual Growth 5y | 10.93% |
| Payout Consistency | 100.0% |
| Payout Ratio | 57.8% |
BNR Growth Ratios
| Growth Correlation 3m | -86.1% |
| Growth Correlation 12m | -49.9% |
| Growth Correlation 5y | -7% |
| CAGR 5y | 3.57% |
| CAGR/Max DD 5y | 0.10 |
| Sharpe Ratio 12m | 0.00 |
| Alpha | -26.60 |
| Beta | 0.481 |
| Volatility | 25.92% |
| Current Volume | 531.6k |
| Average Volume 20d | 223.6k |
| Stop Loss | 52.5 (-3%) |
| Signal | -0.95 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (423.0m TTM) > 0 and > 6% of Revenue (6% = 960.0m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -1.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.86% (prev 13.44%; Δ -3.58pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 907.8m > Net Income 423.0m (YES >=105%, WARN >=100%) |
| Net Debt (33.7m) to EBITDA (1.30b) ratio: 0.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (144.4m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 25.04% (prev 19.05%; Δ 5.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 144.4% (prev 142.6%; Δ 1.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.63 (EBITDA TTM 1.30b / Interest Expense TTM 162.4m) >= 6 (WARN >= 3) |
Altman Z'' 3.04
| (A) 0.15 = (Total Current Assets 4.71b - Total Current Liabilities 3.13b) / Total Assets 10.79b |
| (B) 0.33 = Retained Earnings (Balance) 3.55b / Total Assets 10.79b |
| (C) 0.07 = EBIT TTM 752.0m / Avg Total Assets 11.08b |
| (D) 0.53 = Book Value of Equity 3.46b / Total Liabilities 6.55b |
| Total Rating: 3.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.14
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 5.34% = 2.67 |
| 3. FCF Margin 3.66% = 0.92 |
| 4. Debt/Equity 0.84 = 2.16 |
| 5. Debt/Ebitda 2.72 = -1.34 |
| 6. ROIC - WACC 4.96% = 6.20 |
| 7. RoE 9.38% = 0.78 |
| 8. Rev. Trend -82.34% = -4.12 |
| 9. Rev. CAGR -9.56% = -1.59 |
| 10. EPS Trend -61.83% = -1.55 |
| 11. EPS CAGR -45.76% = -2.50 |
What is the price of BNR shares?
Over the past week, the price has changed by -2.10%, over one month by -4.98%, over three months by -9.04% and over the past year by -13.86%.
Is Brenntag SE a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BNR is around 51.19 EUR . This means that BNR is currently overvalued and has a potential downside of -5.45%.
Is BNR a buy, sell or hold?
What are the forecasts/targets for the BNR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.8 | 16.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 55.6 | 2.7% |
BNR Fundamental Data Overview
Market Cap EUR = 7.96b (7.96b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 531.7m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 18.7551
P/E Forward = 10.8578
P/S = 0.4976
P/B = 1.8905
Beta = 0.726
Revenue TTM = 16.00b EUR
EBIT TTM = 752.0m EUR
EBITDA TTM = 1.30b EUR
Long Term Debt = 3.41b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 125.3m EUR (from shortTermDebt, last quarter)
Debt = 3.54b EUR (Calculated: Short Term 125.3m + Long Term 3.41b)
Net Debt = 33.7m EUR (from netDebt column, last quarter)
Enterprise Value = 10.97b EUR (7.96b + Debt 3.54b - CCE 531.7m)
Interest Coverage Ratio = 4.63 (Ebit TTM 752.0m / Interest Expense TTM 162.4m)
FCF Yield = 5.34% (FCF TTM 586.1m / Enterprise Value 10.97b)
FCF Margin = 3.66% (FCF TTM 586.1m / Revenue TTM 16.00b)
Net Margin = 2.64% (Net Income TTM 423.0m / Revenue TTM 16.00b)
Gross Margin = 25.04% ((Revenue TTM 16.00b - Cost of Revenue TTM 11.99b) / Revenue TTM)
Tobins Q-Ratio = 3.17 (Enterprise Value 10.97b / Book Value Of Equity 3.46b)
Interest Expense / Debt = 1.06% (Interest Expense 37.6m / Debt 3.54b)
Taxrate = 26.78% (from yearly Income Tax Expense: 198.9m / 742.6m)
NOPAT = 550.6m (EBIT 752.0m * (1 - 26.78%))
Current Ratio = 1.50 (Total Current Assets 4.71b / Total Current Liabilities 3.13b)
Debt / Equity = 0.84 (Debt 3.54b / last Quarter total Stockholder Equity 4.21b)
Debt / EBITDA = 2.72 (Net Debt 33.7m / EBITDA 1.30b)
Debt / FCF = 6.04 (Debt 3.54b / FCF TTM 586.1m)
Total Stockholder Equity = 4.51b (last 4 quarters mean)
RoA = 3.92% (Net Income 423.0m, Total Assets 10.79b )
RoE = 9.38% (Net Income TTM 423.0m / Total Stockholder Equity 4.51b)
RoCE = 9.49% (Ebit 752.0m / (Equity 4.51b + L.T.Debt 3.41b))
RoIC = 10.59% (NOPAT 550.6m / Invested Capital 5.20b)
WACC = 5.63% (E(7.96b)/V(11.50b) * Re(7.79%)) + (D(3.54b)/V(11.50b) * Rd(1.06%) * (1-Tc(0.27)))
Shares Correlation 5-Years: -87.20 | Cagr: -1.68%
Discount Rate = 7.79% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.29% ; FCFE base≈680.0m ; Y1≈680.0m ; Y5≈721.3m
Fair Price DCF = 88.37 (DCF Value 12.76b / Shares Outstanding 144.4m; 5y FCF grow -0.60% → 3.0% )
Revenue Correlation: -82.34 | Revenue CAGR: -9.56%
Rev Growth-of-Growth: 11.54
EPS Correlation: -61.83 | EPS CAGR: -45.76%
EPS Growth-of-Growth: -32.53